DK2040734T3 - Antisekretorisk protein til anvendelse til behandling af kompartmentsyndrom - Google Patents
Antisekretorisk protein til anvendelse til behandling af kompartmentsyndromInfo
- Publication number
- DK2040734T3 DK2040734T3 DK07748078.8T DK07748078T DK2040734T3 DK 2040734 T3 DK2040734 T3 DK 2040734T3 DK 07748078 T DK07748078 T DK 07748078T DK 2040734 T3 DK2040734 T3 DK 2040734T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- compartment syndrome
- tumour
- antisecretory
- antisecretory protein
- Prior art date
Links
- 206010010121 compartment syndrome Diseases 0.000 title abstract 3
- 230000001262 anti-secretory effect Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108010038288 antisecretory factor Proteins 0.000 abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 238000001126 phototherapy Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Dispersion Chemistry (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0600933 | 2006-04-27 | ||
| PCT/SE2007/000413 WO2007126363A2 (en) | 2006-04-27 | 2007-04-27 | Antisecretory protein for use in the treatment of compartment syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2040734T3 true DK2040734T3 (da) | 2012-01-23 |
Family
ID=38655929
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07748080.4T DK2037950T3 (da) | 2006-04-27 | 2007-04-27 | Yderligere medicinske anvendelser af antisekretorisk protein |
| DK07748078.8T DK2040734T3 (da) | 2006-04-27 | 2007-04-27 | Antisekretorisk protein til anvendelse til behandling af kompartmentsyndrom |
| DK10188590.3T DK2363140T3 (en) | 2006-04-27 | 2007-04-27 | ANTI-SECRETORIC PROTEIN TO USE IN THE TREATMENT OF COMPARTMENT SYNDROME |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07748080.4T DK2037950T3 (da) | 2006-04-27 | 2007-04-27 | Yderligere medicinske anvendelser af antisekretorisk protein |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10188590.3T DK2363140T3 (en) | 2006-04-27 | 2007-04-27 | ANTI-SECRETORIC PROTEIN TO USE IN THE TREATMENT OF COMPARTMENT SYNDROME |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8309513B2 (enExample) |
| EP (2) | EP2363140B1 (enExample) |
| JP (2) | JP5323682B2 (enExample) |
| KR (3) | KR20090045148A (enExample) |
| CN (3) | CN101460187B (enExample) |
| AT (1) | ATE526031T1 (enExample) |
| AU (1) | AU2007244003B2 (enExample) |
| BR (2) | BRPI0710794A2 (enExample) |
| CA (1) | CA2650589C (enExample) |
| DK (3) | DK2037950T3 (enExample) |
| ES (3) | ES2374712T3 (enExample) |
| IL (1) | IL194774A (enExample) |
| MX (1) | MX2008013774A (enExample) |
| NZ (2) | NZ572257A (enExample) |
| PL (2) | PL2040734T3 (enExample) |
| RU (2) | RU2465914C2 (enExample) |
| SG (1) | SG171601A1 (enExample) |
| WO (1) | WO2007126363A2 (enExample) |
| ZA (2) | ZA200809114B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007244005B2 (en) * | 2006-04-27 | 2012-08-02 | Lantmannen As-Faktor Ab | Further medical uses of antisecretory protein |
| SG171602A1 (en) | 2006-04-27 | 2011-06-29 | Lantmaennen As Faktor Ab | Use of antisecretory factors for treating intraocular hypertension |
| CN101460187B (zh) | 2006-04-27 | 2014-11-05 | 兰特门内阿斯-法克托尔公司 | 抗分泌蛋白的进一步医疗应用 |
| US9962424B2 (en) | 2007-04-27 | 2018-05-08 | Lantmännen As-Faktor Ab | Use of antisecretory factors (AF) for optimizing cellular uptake |
| US8901083B2 (en) | 2008-11-25 | 2014-12-02 | Temple University | Administration of angiocidin for the treatment of leukemia |
| EP2396024A4 (en) * | 2009-02-11 | 2013-02-27 | Lantmaennen As Faktor Ab | USE OF ANTISECRREATORY FACTORS (AF) FOR OPTIMIZATION OF CELLULAR ABSORPTION |
| JP6707121B2 (ja) | 2015-07-10 | 2020-06-10 | ラントメネン・アーエス−ファクトール・アーベー | 高含量のａｆ−１６を有する卵黄の産生方法 |
| MX2019000594A (es) | 2016-07-18 | 2019-09-09 | Lantmaennen As Faktor Ab | Factor anti-secretor 17. |
| JP7217760B2 (ja) * | 2018-06-28 | 2023-02-03 | ラントメネン・メディカル・アーベー | 急性呼吸不全の治療および／または予防の使用のための抗分泌因子 |
| EP3855935A1 (en) | 2018-09-28 | 2021-08-04 | Lantmännen Functional Foods AB | A consumable product comprising malted wheat |
| EP3855934A2 (en) | 2018-09-28 | 2021-08-04 | Lantmännen Functional Foods AB | A consumable product comprising malted dehulled oat |
| CN115605214A (zh) | 2020-03-26 | 2023-01-13 | 兰特门内保健食品公司（Se） | 用于促进身体活动恢复的包含麦芽化谷物的可消耗产品 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH682716A5 (de) * | 1992-01-13 | 1993-11-15 | Christian Fricker | Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung. |
| US5585401A (en) | 1994-12-09 | 1996-12-17 | The Reents Of The University Of California | Method for enhancing outflow of aqueous humor in treatment of glaucoma |
| SE508609C2 (sv) | 1995-08-24 | 1998-10-19 | Rural Patent Svenska Ab | Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning |
| SE506486C2 (sv) * | 1996-11-20 | 1997-12-22 | Svenska Lantmaennen Riksfoerbu | Födoämne som vid förtäring inducerar antisekretoriska proteiner |
| SE513496C2 (sv) * | 1998-12-17 | 2000-09-18 | Rural Patent Svenska Ab | NASP-berikad äggula samt dess användning |
| US7662169B2 (en) * | 2000-09-05 | 2010-02-16 | Wittmann Dietmar H | Prosthesis and method for lowering abdominal pressure |
| GB0322645D0 (en) * | 2003-09-26 | 2003-10-29 | Melacure Therapeutics Ab | Use of antisecretory factor peptides |
| AU2007244005B2 (en) | 2006-04-27 | 2012-08-02 | Lantmannen As-Faktor Ab | Further medical uses of antisecretory protein |
| CN101460187B (zh) | 2006-04-27 | 2014-11-05 | 兰特门内阿斯-法克托尔公司 | 抗分泌蛋白的进一步医疗应用 |
| WO2009052478A1 (en) * | 2007-10-19 | 2009-04-23 | Trustees Of Boston University | Metabolic and cardioprotection by the myokine follistatin-like 1 polypeptide |
-
2007
- 2007-04-27 CN CN200780014997.4A patent/CN101460187B/zh not_active Expired - Fee Related
- 2007-04-27 EP EP10188590.3A patent/EP2363140B1/en active Active
- 2007-04-27 EP EP07748078A patent/EP2040734B1/en active Active
- 2007-04-27 JP JP2009507631A patent/JP5323682B2/ja active Active
- 2007-04-27 AU AU2007244003A patent/AU2007244003B2/en active Active
- 2007-04-27 RU RU2008146734/15A patent/RU2465914C2/ru active
- 2007-04-27 CN CN201510082714.6A patent/CN104689299B/zh active Active
- 2007-04-27 KR KR1020087029120A patent/KR20090045148A/ko not_active Ceased
- 2007-04-27 DK DK07748080.4T patent/DK2037950T3/da active
- 2007-04-27 CA CA2650589A patent/CA2650589C/en active Active
- 2007-04-27 RU RU2008146731/15A patent/RU2457853C2/ru active
- 2007-04-27 DK DK07748078.8T patent/DK2040734T3/da active
- 2007-04-27 WO PCT/SE2007/000413 patent/WO2007126363A2/en not_active Ceased
- 2007-04-27 PL PL07748078T patent/PL2040734T3/pl unknown
- 2007-04-27 KR KR1020147032781A patent/KR101805973B1/ko not_active Expired - Fee Related
- 2007-04-27 BR BRPI0710794-3A patent/BRPI0710794A2/pt not_active IP Right Cessation
- 2007-04-27 SG SG201102875-0A patent/SG171601A1/en unknown
- 2007-04-27 PL PL10188590T patent/PL2363140T3/pl unknown
- 2007-04-27 AT AT07748078T patent/ATE526031T1/de not_active IP Right Cessation
- 2007-04-27 NZ NZ572257A patent/NZ572257A/en not_active IP Right Cessation
- 2007-04-27 CN CN200780014998.9A patent/CN101437533B/zh active Active
- 2007-04-27 MX MX2008013774A patent/MX2008013774A/es active IP Right Grant
- 2007-04-27 ES ES07748078T patent/ES2374712T3/es active Active
- 2007-04-27 KR KR1020147027241A patent/KR101757523B1/ko active Active
- 2007-04-27 ES ES10188590.3T patent/ES2615515T3/es active Active
- 2007-04-27 DK DK10188590.3T patent/DK2363140T3/en active
- 2007-04-27 ES ES07748080.4T patent/ES2472737T3/es active Active
- 2007-04-27 BR BRPI0710858-3A patent/BRPI0710858A2/pt not_active Application Discontinuation
- 2007-04-27 NZ NZ572256A patent/NZ572256A/en not_active IP Right Cessation
-
2008
- 2008-10-22 IL IL194774A patent/IL194774A/en active IP Right Grant
- 2008-10-23 ZA ZA200809114A patent/ZA200809114B/xx unknown
- 2008-10-23 ZA ZA200809116A patent/ZA200809116B/xx unknown
- 2008-10-27 US US12/289,389 patent/US8309513B2/en active Active
-
2010
- 2010-11-02 JP JP2010245989A patent/JP5285043B2/ja active Active
-
2011
- 2011-02-11 US US13/025,702 patent/US8389468B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2040734T3 (da) | Antisekretorisk protein til anvendelse til behandling af kompartmentsyndrom | |
| CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
| CY1123258T1 (el) | Μεθοδος θεραπειας για τον καρκινο | |
| CR9312A (es) | Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| CY1121735T1 (el) | 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου | |
| CY1111065T1 (el) | Φαρμακευτικη συνθεση που περιεχει μια ωμεγα-καρβοξυαρυλ υποκατεστημενη διφαινυλ ουρια για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| BR112019021822A2 (pt) | Terapia de combinação | |
| DK2305255T3 (da) | Arylurinstofforbindelser i kombination med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere | |
| MX390506B (es) | Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer. | |
| NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
| EA201290356A1 (ru) | Композиции для лечения тошноты и рвоты центрального происхождения | |
| EA200802332A1 (ru) | Пирролопиримидины и их применение | |
| CU24046B1 (es) | Compuestos peptídicos que inhiben el virus de la hepatitis c | |
| ATE511889T1 (de) | Partikeltherapieanlage | |
| CY1117394T1 (el) | Λιξισενατιδη για χρηση στην θεραπευτικη αντιμετωπιση της στενωσης ή/και αποφραξης στο συστημα παγκρεατικων πορων | |
| DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
| NO20075849L (no) | Fremgangsmater og preparater til behandling eller forebygging av kreft | |
| EA201070636A1 (ru) | Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения | |
| NO20084749L (no) | Organiske forbindelser og deres anvendelser | |
| UY32554A (es) | Compuestos peptidomiméticos de sulfonamida y usos antivirales de los mismos | |
| EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
| EA201300421A1 (ru) | Комбинированная терапия для лечения инфекции hcv | |
| BR112022012283A2 (pt) | Combinações | |
| MX387726B (es) | Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer. |